AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8424297
Drug: Combined thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined thoracic epidural anaesthesia/light general anaesthesia with continuous epidural bupivacaine 10 mg.h‐1 and morphine 0.2 mg.h‐1 for 38 h after surgery plus systemic ibuprofen 600 mg x 8 h‐1
Trial: 8424297
Drug: General anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthesia and postoperative analgesia with systemic morphine and ibuprofen 600 mg x 8 h‐1
Trial: 3117467
Drug: Nitroglycerin-TTS 5
RxNorm normalized name: nitroglycerin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin-TTS 5 mg/24 h
Trial: 3117467
Drug: Long-acting nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting nitroglycerin tablets, 10.4 mg daily
Trial: 31910658
Drug: DSR solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSR solution (sodium-free 10% dextrose)
Trial: 31910658
Drug: Standard PD
RxNorm normalized name: PD-0299685
DrugBank: PD-0299685 (DB15264)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard PD solution (Dianeal 4.25% dextrose)
Trial: 30120404
Drug: DHA-CHO-VE treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-CHO-VE treatment
Trial: 27621162
Drug: Nifedipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (30 mg controlled release twice a day)
Trial: 23944684
Drug: High-caloric food
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-caloric food supplement with high fat content
Trial: 23944684
Drug: High-caloric food
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-caloric food supplement with high carbohydrate content
Trial: 19082800
Drug: Shengmai injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shengmai injection (SMI)
Trial: 12821964
Drug: Intensive diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive diet therapy (6000-7000 kJ/day or 1400-1700 kcal/day) with weekly dietitian contact for 12 weeks
Trial: 10364866
Drug: Ketamine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 2.5 mg.kg‐1
Trial: 8322572
Drug: Thiopentone 5
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopentone 5 mg.kg‐1
Trial: 2222943
Drug: Intravenous captopril
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous captopril
Trial: 6301671
Drug: Adriamycin (doxorubicin)
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin (doxorubicin) 50 mg/m2 IV every three weeks
Trial: 6301671
Drug: Adriamycin (doxorubicin)
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin (doxorubicin) 75 mg/m2 IV every three weeks
Trial: 26559482
Drug: Topical imiquimod-cream
RxNorm normalized name: Imiquimod Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical imiquimod-cream followed by intradermal trivalent influenza vaccine (INF-Q-ID)
Trial: 26559482
Drug: Topical aqueous-cream
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical aqueous-cream control followed by intradermal trivalent influenza vaccine (INF-C-ID)
Trial: 26559482
Drug: Topical aqueous-cream
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical aqueous-cream control followed by intramuscular trivalent influenza vaccine (INF-C-IM)
Trial: 26559482
Drug: Topical imiquimod-cream
RxNorm normalized name: Imiquimod Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical imiquimod-cream followed by intradermal normal-saline injection (SAL-Q-ID)
Trial: 12094862
Drug: 60‐100 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60‐100 mg/day prednisolone equivalent, tapered to 10‐15 mg/day within 6 weeks and maintained for another 4 weeks
Trial: 12094862
Drug: Steroid resistant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid resistant patients
Trial: 9685127
Drug: Dextran 40
RxNorm normalized name: Dextran 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextran 40 infusion for 72 hours after surgery
Trial: 9685127
Drug: No dextran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No dextran 40 infusion
Trial: 8600180
Drug: Intravenous pilocarpine
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous pilocarpine (P)
Trial: 12789172
Drug: Azelaic acid
RxNorm normalized name: Azelaic Acid
DrugBank: Azelaic acid (DB00548)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azelaic acid (15%) gel
Trial: 2884152
Drug: Loratadine 40
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loratadine 40 mg once daily
Trial: 2266679
Drug: Aluminum hydroxide
RxNorm normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum hydroxide gel (Al[OH]3) (5 ml) alone
Trial: 2266679
Drug: Al[OH]3 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Al[OH]3 (5 ml) plus calcium acetate (Ca acetate) (1330 mg)
Trial: 2266679
Drug: Al[OH]3 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Al[OH]3 (5 ml) plus calcium citrate (Ca citr) (950 mg)
Trial: 24274323
Drug: High-fiber snacks
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fiber snacks (10-12 g dietary fiber per day)
Trial: 21262918
Drug: Fructo-oligosaccharides (FOS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructo-oligosaccharides (FOS) 15 g/day for 4 weeks
Trial: 7816008
Drug: Intravenous calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous calcitriol (IVC)
Trial: 7816008
Drug: Oral calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcitriol (ORC)
Trial: 3281679
Drug: Acipimox (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (400 mg t.i.d. for type II patients, 250 mg t.i.d. for type IV patients)
Trial: 3281679
Drug: Acipimox (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (400 mg t.i.d. for type II patients)
Trial: 25413485
Drug: IV analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV analgesia (piritramide 7.5 mg IV, plus oral metamizole)
Trial: 22111896
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (EPA) and cyclo-oxygenase-2 (COX-2) inhibitor celecoxib with progressive resistance training (PRT) and essential amino acids high in leucine.
Trial: 22111896
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (EPA) and cyclo-oxygenase-2 (COX-2) inhibitor celecoxib.
Trial: 16841563
Drug: Aripiprazole (10-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (10-15 mg/day)
Trial: 16841563
Drug: Haloperidol (9-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (9-15 mg/day)
Trial: 12581571
Drug: GI ‐‐>
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GI ‐‐> VC regimen (gemcitabine 1000 mg/m² + ifosfamide 1500 mg/m² followed by vinorelbine 25 mg/m² + cisplatin 100 mg/m²)
Trial: 12581571
Drug: VC ‐‐>
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VC ‐‐> GI regimen (vinorelbine 25 mg/m² + cisplatin 100 mg/m² followed by gemcitabine 1000 mg/m² + ifosfamide 1500 mg/m²)
Trial: 12581571
Drug: VC regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VC regimen (vinorelbine 25 mg/m² + cisplatin 100 mg/m²)
Trial: 12581571
Drug: GC regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC regimen (gemcitabine 1400 mg/m² + cisplatin 100 mg/m²)
Trial: 11127169
Drug: Consultation behaviour
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Consultation behaviour for significant new onset symptoms (rectal bleeding, abdominal pain, change in bowel habit).
Trial: 8737130
Drug: sparfloxacin 200
RxNorm normalized name: sparfloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sparfloxacin 200 mg once daily for 5 days following a loading dose of 400 mg on day 1
Trial: 8737130
Drug: cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cefuroxime axetil 250 mg twice daily for 8 days
Trial: 1317697
Drug: preoperative etoposide‐platinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: preoperative etoposide‐platinum (EP) chemotherapy‐surgery‐postoperative EP
Trial: 29632222
Drug: Aspirin use
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin use (solo practices)
Trial: 26443196
Drug: Clopidogrel napadisilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel napadisilate 75 mg
Trial: 23026843
Drug: Clopidogrel bisulfate
RxNorm normalized name: Clopidogrel Bisulfate
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel bisulfate 75 mg
Trial: 24532997
Drug: Armodafinil 200
RxNorm normalized name: armodafinil 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armodafinil 200 mg once daily
Trial: 21874559
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg bilastine
Trial: 23742030
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg bilastine
Trial: 23742030
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg bilastine
Trial: 20008947
Drug: Olanzapine long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine long-acting injection (high dose, 300 mg every 2 weeks)
Trial: 20008947
Drug: Olanzapine long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine long-acting injection (medium dose, 405 mg every 4 weeks)
Trial: 20008947
Drug: Olanzapine long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine long-acting injection (low dose, 150 mg every 2 weeks)
Trial: 20008947
Drug: Olanzapine long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine long-acting injection (very low dose, 45 mg every 4 weeks)
Trial: 20008947
Drug: Olanzapine long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine long-acting injection (all doses combined)
Trial: 20008947
Drug: Olanzapine long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine long-acting injection (high dose)
Trial: 20008947
Drug: Olanzapine long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine long-acting injection (medium dose)
Trial: 20008947
Drug: Olanzapine long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine long-acting injection (low dose)
Trial: 20008947
Drug: Olanzapine long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine long-acting injection (very low dose)
Trial: 20008947
Drug: Olanzapine long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine long-acting injection and oral olanzapine
Trial: 20008947
Drug: Olanzapine long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine long-acting injection
Trial: 20938374
Drug: Podophyllotoxin 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Podophyllotoxin 0.5% solution
Trial: 12902571
Drug: Podophyllotoxin 0.15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Podophyllotoxin 0.15% cream
Trial: 12902571
Drug: Podophyllotoxin solution
RxNorm normalized name: podophyllotoxin
DrugBank: Podofilox (DB01179)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Podophyllotoxin solution
Trial: 12902571
Drug: Podophyllotoxin cream
RxNorm normalized name: podophyllotoxin
DrugBank: Podofilox (DB01179)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Podophyllotoxin cream
Trial: 2117741
Drug: Overnight, 12-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overnight, 12-hour nasogastric infusions plus daytime oral feedings (group 2)
Trial: 2117741
Drug: Oral feedings
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral feedings alone (group 3)
Trial: 22577906
Drug: Morphine 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 7.5 mg
Trial: 18571875
Drug: Integrated CD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated CD and primary care during the index treatment episode
Trial: 16781291
Drug: Famciclovir single-dose
RxNorm normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Famciclovir single-dose (1500 mg once)
Trial: 16781291
Drug: Famciclovir single-day
RxNorm normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Famciclovir single-day (750 mg twice a day for 1 day)
Trial: 31299013
Drug: Nonstudy oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonstudy oral PrEP use
Trial: 31299013
Drug: Oral PrEP
RxNorm normalized name: Iron bivalent, oral preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral PrEP users
Trial: 31299013
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of oral PrEP after study completion
Trial: 24825486
Drug: Sustained-release methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release methylphenidate (MPH-SR)
Trial: 12240793
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg/day for 4 weeks
Trial: 10406816
Drug: Beta-blockade therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockade therapy
Trial: 8884862
Drug: Duraflo II
RxNorm normalized name: Duraflor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duraflo II heparin-coated circuit
Trial: 6339595
Drug: Dutimelan 8-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutimelan 8-15 regimen (DTM 8-15): 7 mg of prednisolone acetate and 4 mg of prednisolone alcohol at 8 A.M., 15 mg of cortisone acetate and 3 mg of prednisolone alcohol at 3 P.M., placebo at 8 P.M.
Trial: 6339595
Drug: Placebo at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo at 8 A.M., 15 mg of cortisone acetate and 3 mg of prednisolone alcohol at 3 P.M., 7 mg of prednisolone acetate and 4 mg of prednisolone alcohol at 8 P.M. (Rx 15-20).
Trial: 29862925
Drug: Psychodynamic online
RxNorm normalized name: FILTER,SUCTION,INLINE #FHBF200S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychodynamic online treatment
Trial: 24638270
Drug: Low dose-fractionation
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low dose-fractionation (LD) group, total doses of 55 Gy and 44 Gy in 22 fractions to PTV1 and PTV2, respectively.
Trial: 24638270
Drug: High dose-fractionation
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose-fractionation (HD) group, total doses of 66 Gy and 55 Gy in 22 fractions to PTV1 and PTV2, respectively.
Trial: 12107606
Drug: 100 microg
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg BDP as one inhalation from 100‐microg/actuation strength
Trial: 8703667
Drug: HN-65021 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HN-65021 (5 mg)
Trial: 8703667
Drug: HN-65021 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HN-65021 (10 mg)
Trial: 8703667
Drug: HN-65021 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HN-65021 (100 mg)
Trial: 28528015
Drug: Exposure-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-based cognitive behavior therapy (CBT)
Trial: 30644767
Drug: Exposure-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-based cognitive behavior therapy (CBT) and Psychoeducation plus relaxation training (PRT)
Trial: 19583078
Drug: Remifentanil continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil continuous infusion of 0.4 microg x kg(‐1) x mn(‐1) (GR n = 15)
Trial: 2693996
Drug: Oxiracetam (800-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxiracetam (800-mg tablets), given twice daily for 12 weeks
Trial: 2693996
Drug: Placebo, given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, given twice daily for 12 weeks
Trial: 30659024
Drug: SoC EGFR-TKI
RxNorm normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SoC EGFR-TKI (gefitinib 250 mg or erlotinib 150 mg, orally, once daily)
Trial: 28753958
Drug: MNP+Fe (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MNP+Fe (12.5 mg iron)
Trial: 22344561
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin (160 IU) administered postprandially after lunch
Trial: 22344561
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin (160 IU) administered in the fasted state
Trial: 22344561
Drug: Placebo (vehicle)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle) administered postprandially after lunch
Trial: 15212189
Drug: Intravenous 5-isosorbide
RxNorm normalized name: hydralazine
DrugBank: Hydralazine (DB01275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous 5-isosorbide mononitrate (5-ISMN)
Trial: 9743398
Drug: bupivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine with sufentanil 0.5 microg/ml
Trial: 9743398
Drug: bupivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine with sufentanil 1 microg/ml
Trial: 9743398
Drug: bupivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine with sufentanil 1.5 microg/ml
Trial: 30965213
Drug: Prophylactic amoxicillin/clavulanic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic amoxicillin/clavulanic acid from day 29 after the start of treatment until 14 days after completion of chemoradiotherapy
Trial: 30965213
Drug: Prophylactic amoxicillin/clavulanic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic amoxicillin/clavulanic acid
Trial: 24916838
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) insulin (duration 48 h)
Trial: 20970238
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of TGCS interventions
Trial: 18425015
Drug: Preoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiation therapy (for patients unable to walk at surgery)
Trial: 8241527
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg nocte)
Trial: 8241527
Drug: Ebrotidine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebrotidine (800 mg nocte)
Trial: 8241527
Drug: Ranitidine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine and Ebrotidine (both treatments)
Trial: 3531860
Drug: Interferon alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alpha-2b (1 X 10(6) IU) injected into warts three times weekly for three weeks
Trial: 3531860
Drug: Placebo injected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injected into warts three times weekly for three weeks
Trial: 22471290
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg twice daily
Trial: 22471290
Drug: Aspirin 200
RxNorm normalized name: aspirin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 200 mg once daily
Trial: 18339977
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine plus insulin lispro
Trial: 18339977
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin plus unmodified human insulin
Trial: 1555991
Drug: Preoperative hyperthermia
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative hyperthermia with radiation therapy (5000‐5040 cGy at 180‐200 cGy per fraction, hyperthermia delivered 30‐60 minutes after radiation for 60 minutes)
Trial: 1555991
Drug: One hyperthermia
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One hyperthermia treatment per week for a total of five treatments
Trial: 1555991
Drug: Two hyperthermia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two hyperthermia treatments per week for a total of ten treatments
Trial: 4003284
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) nifedipine (0.1, 0.2 and 0.4 microgram/kg/min over 10 minutes each)
Trial: 4003284
Drug: Chronic oral
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic oral nifedipine (60 mg/day) in combination with atenolol